Of note, ETBR overexpression was correlated with shorter patient survival or poor patient outcome in small-cell lung cancer, vulvar cancer, clear-cell renal cell carcinoma, esophageal squamous cell carcinoma, and GBM [5–7, 12, 24, 27] and may thereby represent a potential prognostic marker as well as a therapeutic target for several cancer forms. This evidence concerns the gene EDNRB and glioblastoma.